GBIO (Generation Bio) Earnings per share for the last four quarters
Generation Bio Co. (GBIO) possesses significant pricing power due to the low demand elasticity for genome editing and its innovative ceDNA delivery system. Business profitability relies on partnerships with pharma behemoths, royalties, and the commercialization of non-viral therapies. This price chart reflects the EPS TTM trend, which currently stands at 57.00. Development is conducted in the US within a stable environment free of sanctions risks.
%20%5Blogo%5D%20GBIO&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_GBIO_-_Generation-Bio-Co._-_Net-earnings-per-share-EPS-TTM "GBIO (Generation Bio Co.) Net earnings per share for the last four quarters history from 02/11/2024 to 02/21/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Generation Bio Corp (GBIO)
- current quotes and average value forecast:
- business market valuation indicators:
- business book valuation details:
- company total debt and liquidity indicators:
Debt to Equity Ratio Generation Bio Co.|GBIO - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Generation Bio Co.|GBIO - Company Aggregate Debts|Debt to Book Capitalization Ratio Generation Bio Co|GBIO - Company Long-Term Debts|Short-Term Debt Volume Generation Bio|Immediate Liquidity generationbio.com
- business earnings and investment ratios data:
GBIO - Net Income|Expected Net Income Generation Bio Co.|GBIO - P/E Multiple|Projected Price to Earnings Generation Bio Co.|GBIO - Price/Earnings to Growth Ratio|Company Value to EBITDA Generation Bio Co|GBIO - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Generation Bio|GBIO - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year generationbio.com|GBIO - Earnings growth in current year|Net earnings per share growth forecast for next year Generation Bio Co.
Fundamental company valuation:Generation Bio - GBIO
EPS (TTM) dynamics measure the rate of change in net income per share over twelve months, allowing investors to differentiate real capital growth from short-term market fluctuations. By analyzing the annual EPS (TTM) growth statistics, one can assess the scaling efficiency of the non-viral gene delivery systems developed by the management of Generation Bio Co. (GBIO) to ensure the mass adoption of therapy.
Competitor analysis for Generation Bio Co.
TEM - Net earnings per share (EPS TTM)|QGEN (Qiagen) - Net earnings per share for the last 12 months|IONS: Earnings per share for the last four quarters|RGEN (Repligen Corp.) - Net earnings per share (EPS TTM)|Avidity Corp (RNA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months CRISPR Therapeutics AG (CRSP)|WGS - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Ultragenyx RARE|BEAM: Earnings per share for the last 12 months|SRPT: Net earnings per share for the last 12 months|Earnings per share for the trailing year TWST (Twist Bioscience Corp)|TXG: Net earnings per share (EPS TTM)|NTLA (intelliatx.com) - Earnings per share for the last twelve months|STOK (Stoke Therapeutics, Inc.) - Net earnings per share (EPS TTM)|BioLife Solutions Inc (BLFS) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Wave Life Sciences Corp (WVE)|MAZE - Net earnings per one share for the last twelve months|Sionna Therapeutics Inc - Net earnings per share for the last 12 months|Earnings per share for the trailing year PRME|Taysha Gene Therapies, Inc. - Net earnings per share (EPS TTM)|uniQure NV (QURE) - Net earnings per share for the last 12 months|MeiraGTx PLC (MGTX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months REGENXBIO Corp (RGNX)|Net earnings per share for the last 12 months SLDB|ocugen.com (OCGN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) PACB|Benitec Biopharma Inc (BNTC) - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) DSGN (Design Pharma)|Rocket Corp - Earnings per share for the last twelve months|4D Molecular Therapeutics - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Lexeo Therapeutics LXEO|korrobio.com (KRRO) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Editas Medicine Inc (EDIT)|SLN (Silence Therapeutics Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months PRQR (ProQR Therapeutics NV)|Earnings per share for the last twelve months Codexis, Inc. (CDXS)|sangamo.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NAUT (Nautilus Bio)|Net earnings per share (EPS TTM) Metagenomi Inc. MGX|Precision BioSciences - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Boundless Bio Inc (BOLD)|XCUR: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Imunon (IMNN)|Earnings per share for the last twelve months Phio Pharmaceuticals Corp|Earnings per share for the last 12 months MBIO (Mustang Bio Corp)|Net earnings per share (EPS TTM) RNAZ|BNGO - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Applied DNA Sciences APDN|Earnings per share for the trailing year BLUE|ImmunoPrecise - Net earnings per share (EPS TTM)|OMGA - Net earnings per share (EPS TTM)|OMIC (Singular Genomics Systems Inc) - Net earnings per share for the last 12 months|RGLS: Earnings per share for the last four quarters|SYRS (Syros Pharmaceuticals) - Net earnings per share (EPS TTM)|telesisbio.com (TBIO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months TRACON Pharmaceuticals, Inc. (TCON)|UBX - Net earnings per one share for the last twelve months
